Flag of the European Union EU Clinical Trials Register Help

Clinical trials for TNF inhibitor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    127 result(s) found for: TNF inhibitor. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2007-001694-28 Sponsor Protocol Number: Version 1 Start Date*: 2007-05-10
    Sponsor Name:Department of Rheumatology, Hvidovre Hospital
    Full Title: SPARTA – spondyloarthritis remission trial after adalimumab
    Medical condition: Spondyloarthropaties and ankylosing spondyllitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-002284-42 Sponsor Protocol Number: NL51186.048.14 Start Date*: 2015-09-18
    Sponsor Name:READE
    Full Title: INTENT: immunogenicity in patients failing response on anti-TNF -Immunogenicity and pharmacokinetics in patients failing to respond to TNF inhibitors (phase 1); -Clinical effectiveness of subseq...
    Medical condition: rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001021-10 Sponsor Protocol Number: SAHL1011 Start Date*: 2018-08-06
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: Brodalumab in a randomised, open, phase IV study evaluating clinical efficacy in psoriasis patients switching from TNF-alpha inhibitor treatment
    Medical condition: Moderate to severe plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003138-17 Sponsor Protocol Number: P1200_51 Start Date*: 2020-01-17
    Sponsor Name:Cliniques universitaires Saint-Luc
    Full Title: A 24 weeks proof of concept study to evaluate the clinical, MRI and synovial tissue benefit of Sarilumab in active RA patients despite TNF agents
    Medical condition: Medical condition – Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10003268 Arthritis rheumatoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000435-13 Sponsor Protocol Number: JWGKDVAAP0117 Start Date*: 2017-11-13
    Sponsor Name:University Hospital Frankfurt for its Dermatology Department, Clinical Research
    Full Title: Exploratory study to evaluate changes in inflammatory pattern and analysis for serum biomarkers in patients with active, moderate-to-severe hidradenitis suppurativa after 2-week and 6-week treatmen...
    Medical condition: Hidradenitis suppurativa is defined as a chronic inflammatory disease of the intertriginous area, including the axilla, groin and anogenital or submammary regions. The condition is characterized by...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018369-48 Sponsor Protocol Number: CASTIP3 Start Date*: 2011-03-10
    Sponsor Name:Medizinische Universität Wien
    Full Title: Der Einfluss von Adalimumab auf kardiovaskuläre und metabolische Risikofaktoren in der Therapie von Patienten mit mittelschwerer bis schwerer Psoriasis vulgaris im Vergleich zu einer Standardtherap...
    Medical condition: Psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    12.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000815-15 Sponsor Protocol Number: BOS-1168-WEI-0080-I Start Date*: 2011-08-02
    Sponsor Name:Medizinische Fakultät der technischen Universität Muenchen
    Full Title: BOSTRIP (Investigator Initiated Trial) (Biomarkers of systemic treatment response in Psoriasis) Differential analysis of metabolomic profiles in patients with chronic plaque psoriasis underg...
    Medical condition: Psoriasis is a chronic hyperproliferative and inflammatory skin disease with its major subtype, chronic plaque-type psoriasis, affecting approximately 2% of individuals in Western populations. It m...
    Disease:
    Population Age: Elderly Gender:
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001368-46 Sponsor Protocol Number: A3921125 Start Date*: 2013-10-23
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONS...
    Medical condition: Psoriatic arthritis (PsA)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) ES (Completed) SK (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-020738-24 Sponsor Protocol Number: Version 1.2 (20/06/2011) Start Date*: 2010-10-12
    Sponsor Name:King's College London
    Full Title: Optimising Treatment With Tumour Necrosis Factor Inhibitors In Rheumatoid Arthritis: Is Dose Tapering Practical In Good Responders? A “Proof Of Principle” And Exploratory Trial. (OPTTIRA)
    Medical condition: Patients with established Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001682-42 Sponsor Protocol Number: ML 20381 Start Date*: 2006-07-16
    Sponsor Name:Roche AB
    Full Title: Rituximab phase IIIb open-label, multi-centre assessment of safety and effectiveness in patients with RA following inadequate response to one prior anti-TNF inhibitor (RESET).
    Medical condition: Active reumathoid arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002967-28 Sponsor Protocol Number: ABATACEPT-AS-01 Start Date*: 2007-10-19
    Sponsor Name:Charité University Medicine
    Full Title: Pilot open label clinical trial with Abatacept in Ankylosing Spondylitis
    Medical condition: T cell responses have been demonstrated against proteoglycan (an important cartilage protein) in human arthritides including ankylosing spondylitis. We suggest that a chronic, probably T cell media...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003351-37 Sponsor Protocol Number: I4V-MC-JAJA Start Date*: 2019-08-08
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Active Controlled, Parallel Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis.
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) NL (Trial now transitioned) HU (Completed) DE (Restarted) GR (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) LT (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-014348-12 Sponsor Protocol Number: ASIM (IMM 08-0061) Start Date*: 2009-10-13
    Sponsor Name:Mikkel Østergaard
    Full Title: Helkrops MR, MR af sacroiliacaled og columna totalis og cirkulerende biomarkører hos patienter med spondylartritis i behandling med adalimumab (ASIM)
    Medical condition: Spondyloartritis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10051265 Spondyloarthropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-004173-32 Sponsor Protocol Number: 1-10-72-164-15 Start Date*: 2015-12-18
    Sponsor Name:Department of Clinical Biochemestry, Aarhus University Hospital
    Full Title: Personalized medicine: Administration of TNF-alpha inhibitor treatment due to serum concentration measuring. A randomized and investigator initiated study.
    Medical condition: Rheumatic diseases
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000005156 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003260-20 Sponsor Protocol Number: 20140727 Start Date*: 2016-05-04
    Sponsor Name:Leiden University Medical Centre
    Full Title: CHAMP: Children with Arthritis: Monotherapy or Polytherapy. A multicentre, single-blinded, randomized treat to target, one-year follow-up clinical trial in patients with recent onset Juvenile Idiop...
    Medical condition: Juvenile idiopathic arthritis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004572-21 Sponsor Protocol Number: 1368-0010 Start Date*: 2017-06-07
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: Proof-of-concept study of BI 655130 add-on treatment in patients with mild-to-moderately active ulcerative colitis during TNF inhibitor therapy
    Medical condition: Mild-to-moderately active ulcerative colitis on TNF inhibitor therapy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) NO (Prematurely Ended) DE (Completed) NL (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000897-39 Sponsor Protocol Number: GS-US-373-1499 Start Date*: 2017-01-09
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: Evaluation of the Efficacy and Safety of GS-5745 as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Subjects with Moderate to Severe Rheumatoid Arthritis.
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004278-88 Sponsor Protocol Number: GA28950 Start Date*: 2014-06-19
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: PHASE III, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF ETROLIZUMAB DURING INDUCTION AND MAINTENANCE IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLIT...
    Medical condition: Ulcerative colitis (UC)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) GR (Completed) DE (Completed) CZ (Completed) DK (Completed) BE (Completed) HU (Completed) AT (Completed) ES (Completed) NL (Completed) IT (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001103-23 Sponsor Protocol Number: PA0008 Start Date*: 2016-11-21
    Sponsor Name:UCB Biopharma SPRL
    Full Title: A MULTICENTER, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ACTIVE PSORIATIC ARTHRITIS
    Medical condition: psoriatic arthritic
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-000947-41 Sponsor Protocol Number: RC-P0055 Start Date*: 2017-08-18
    Sponsor Name:Groupement des Hôpitaux de l’Institut Catholique de Lille
    Full Title: ABATACEPT VERSUS TOCILIZUMAB BY SUBCUTANEOUS ADMINISTRATION FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN TNF ALPHA INHIBITOR INADEQUATE RESPONDER PATIENTS: A RANDOMIZED, OPEN-LABELED, SUPERIORITY T...
    Medical condition: Adults patients suffering from rheumatoid arthritis and in adequate response to a first line of treatment with a TNF alpha inhibitor.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 12 02:50:19 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA